At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 366 enrolled

Drug / intervention

losartan potassium +2 moredrug

Likely dose

losartan potassium 50 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00887250

NCT00887250Phase 3Completed

Compare CT.gov

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan (MK954, DuP753) in Patients With Mild to

Merck Sharp & Dohme LLC·interventional·Posted Apr 23, 2009·Updated Jul 14, 2009

In Brief

A Phase 3 clinical trial evaluating losartan potassium, Comparator: losartan, and 1 other intervention for Hypertension. Completed, enrolled 366 participants.

Detailed Summary

After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHypertension

Countries--

Collaborators--

Timeline

Phase 3CompletedFinished

1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartDec 1991

Primary CompletionAug 1992

Study CompletionNov 1992

First PostedApr 2009

TodayJul 2026

First PostedApr 23, 2009

Enrollment StartDec 1, 1991

Primary CompletionAug 1, 1992

Study CompletionNov 1, 1992

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 17.2 years ago

Interventions

losartan potassiumdrug

50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.

Comparator: losartandrug

50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.

Comparator: Placebodrug

Placebo to Losartan